Home > Dermatology > EADV 2020 > Upcoming Treatments > Baricitinib in AD: Efficacy paired with consistent long-term results

Baricitinib in AD: Efficacy paired with consistent long-term results

Presented By
Prof. Jonathan Silverberg , George Washington University, USA
Conference
EADV 2020
Trial
Phase 3, BREEZE-AD3
In the phase 3 BREEZE-AD3 trial, baricitinib demonstrated reliable long-term response maintenance in patients with moderate-to-severe atopic dermatitis (AD) for up to 68 weeks. The oral JAK1/JAK2 inhibitor baricitinib has shown significant efficacy in improving signs and symptoms of AD in the 2 independent monotherapy trials BREEZE-AD1 (NCT03334396) and BREEZE-AD2 (NCT03334422) [1]. Patients completing these studies were eligible for enrolment into the presented BREEZE-AD3 (NCT03334435), a double-blind, long-term extension trial to assess baricitinib in patients with moderate-to-severe AD up to 68 weeks [2]. The trial design differed depending...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on